The adenosine A2A receptor agonist CGS 21680 fails to ameliorate the course of dextran sulphate-induced colitis in mice

Inflammation Research

Volumn 56, Issue 5, 2007, Pages 204-209

  Selmeczy, Z ^a   Csoka B ^a   Pacher, P ^b   Vizi, E S ^a   Hasko G ^a,c  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Adenosine A2A receptor; CGS 21680; Colitis; Dextran sulphate

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ACETYLCHOLINE; ADENOSINE A2A RECEPTOR AGONIST; CHEMOKINE; CYTOKINE; DEXTRAN SULFATE; DIMETHYL SULFOXIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; TRITIUM; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE; ADENOSINE A2A RECEPTOR; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1; MIP 2 PROTEIN, MOUSE; MIP-2 PROTEIN, MOUSE; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; COLON; COLON BIOPSY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; INCIDENCE; MALE; MOUSE; MUSCLE; NONHUMAN; RECTUM HEMORRHAGE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE;

ACETYLCHOLINE; ADENOSINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHEMOKINES; COLITIS; DEXTRAN SULFATE; GENE EXPRESSION REGULATION; INTERLEUKIN-1BETA; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MICE; MICE, INBRED STRAINS; MUSCLE, SMOOTH; PHENETHYLAMINES; RECEPTOR, ADENOSINE A2A;

EID: 34250810758     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-6150-7     Document Type: Article

References (61)

1. Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol 2000; 67: 267-78.
2. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000; 49: 9-15.
3. Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci 1999; 44: 1458-75.
4. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-49.
5. Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I et al. Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Protective effect of rebamipide. Scand J Gastroenterol 1996; 31: 985-92.
6. Aube AC, Cherbut C, Barbier M, Xing JH, Roze C, Galmiche JP. Altered myoelectrical activity in noninflamed ileum of rats with colitis induced by trinitrobenzene sulphonic acid. Neurogastroenterol Motil 1999; 11: 55-62.
7. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
8. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114: 385-91.
9. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-67.
10. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997; 280: 988-1000.
11. Sipka S, Nagy K, Szegedi G. Adenosine induced delay of expression of AIDS virus, HIV, in H9T cells. Acta Biochim Biophys Hung 1988; 23: 75-82.
12. Sipka S, Szentmiklosi AJ, Nagy A, Taskov V, Szegedi G. Inhibition of the zymosan-induced chemiluminescence of human phagocytes by adenosine, polyadenylic acid and agents influencing adenosine metabolism. Allergol et Immunopathol 1989; 17: 209-12.
13. Apasov S, Koshiba M, Redegeld F, Sitkovsky MV. Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Immunol Rev 1995; 146: 5-19.
14. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76: 5-13.
15. Hasko G, Szabo C. Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system. Biochem Pharmacol 1998; 56: 1079-87.
16. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
17. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998; 358: 261-8.
18. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998; 125: 379-87.
19. Schrier DJ, Lesch ME, Wright CD, Gilbertsen RB. The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats. J Immunol 1990; 145: 1874-9.
20. Marak GE jr., de Kozak Y, Faure JP, Rao NA, Romero JL, Ward PA et al. Pharmacologic modulation of acute ocular inflammation. I. Adenosine. Ophthalmic Res 1988; 20: 220-6.
21. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci 2003; 24: 66-70.
22. Sipka S, Kovacs I, Szanto S, Szegedi G, Brugos L, Bruckner G et al. Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells. Cytokine 2005; 31: 258-63.
23. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000; 14: 2065-74.
24. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, Gause WC et al. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol 2005; 175: 8260-70.
25. Nemeth ZH, Leibovich SJ, Deitch EA, Sperlagh B, Virag L, Vizi ES et al. Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem Biophys Res Commun 2003; 312: 883-8.
26. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, Boons GJ et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 2003; 163: 711-21.
27. Nemeth ZH, Leibovich SJ, Deitch EA, Vizi ES, Szabo C, Hasko G. cDNA microarray analysis reveals a nuclear factor-kappaB-independent regulation of macrophage function by adenosine. J Pharmacol Exp Ther 2003; 306: 1042-9.
28. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 4634-40.
29. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52.
30. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
31. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996; 156: 3435-42.
32. Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, Franco R et al. IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J Immunol 1999; 162: 3607-14.
33. Mirabet M, Herrera C, Cordero OJ, Mallol J, Lluis C, Franco R. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 1999; 112 (Pt 4): 491-502.
34. Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 2000; 129: 2-11.
35. Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E et al. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br J Pharmacol 2001; 134: 116-26.
36. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 2001; 167: 4026-32.
37. Nemeth ZH, Deitch EA, Szabo C, Mabley JG, Pacher P, Fekete Z et al. Na+/H+ exchanger blockade inhibits enterocyte inflammatory response and protects against colitis. Am J Physiol Gastrointest Liver Physiol 2002; 283: G122-32.
38. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005; 129: 26-33.
39. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005; 93: 310-20.
40. Casati C, Monopoli A, Dionisotti S, Zocchi C, Bonizzoni E, Ongini E. Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: tolerance develops to A1-mediated hemodynamic effects. J Pharmacol Exp Ther 1994; 268: 1506-11.
41. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-20.
42. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 4634-40.
43. Gomez G, Sitkovsky MV. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 2003; 102: 4472-8.
44. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE et al. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 2001; 21: 791-6.
45. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643-52.
46. Hasko G, Xu DZ, Lu Q, Nemeth ZH, Jabush J, Berezina TL et al. Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic shock. Critical care medicine 2006; 34: 1119-25.
47. Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A. Effect of adenosine A2A receptor activation in murine models of respiratory disorders. Am J Physiol Lung Cell Mol Physiol 2005.
48. Ohkusa T, Okayasu I, Tokoi S, Araki A, Ozaki Y. Changes in bacterial phagocytosis of macrophages in experimental ulcerative colitis. Digestion 1995; 56: 159-64.
49. Mabley J, Soriano F, Pacher P, Hasko G, Marton A, Wallace R et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N- methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003; 466: 323-9.
50. Barankiewicz J, Cohen A. Purine nucleotide metabolism in resident and activated rat macrophages in vitro. Eur J Immunol 1985; 15: 627-31.
51. Garcia Soriano F, Liaudet L, Marton A, Hasko G, Batista Lorigados C, Deitch EA et al. Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 2001; 29: 703-8.
52. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 2000; 164: 1013-9.
53. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 2001; 164: 1213-20.
54. Liaudet L, Mabley JG, Pacher P, Virag L, Soriano FG, Marton A et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg 2002; 235: 568-78.
55. Marton A, Pacher P, Murthy KG, Nemeth ZH, Hasko G, Szabo C. Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int J Mol Med 2001; 8: 617-21.
56. Hasko G, Sitkovsky MV, Szabo C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 2004; 25: 152-7.
57. Mabley JG, Pacher P, Liaudet L, Soriano FG, Hasko G, Marton A et al. Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G138-44.
58. Antonioli L, Fornai M, Colucci R, Ghisu N, Blandizzi C, Tacca MD. A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. Inflamm Bowel Dis 2006; 12: 117-22.
59. Kinoshita K, Sato K, Hori M, Ozaki H, Karaki H. Decrease in activity of smooth muscle L-type Ca2+ channels and its reversal by NF-kappaB inhibitors in Crohn's colitis model. Am J Physiol Gastrointest Liver Physiol 2003; 285: G483-93.
60. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
61. Nguyen DK, Montesinos MC, Williams AJ, Kelly M, Cronstein BN. Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J Immunol 2003; 171: 3991-8.